Radiopharmaceutical CRO Market Report Scope and Overview:

The Radiopharmaceutical CRO Market was valued at USD 1.05 Billion in 2025 and is projected to reach USD 2.40 Billion by 2035, growing at a CAGR of 8.60% during the forecast period.

The Radiopharmaceutical CRO Market continues to expand as an accelerating pipeline of diagnostic and therapeutic radiopharmaceuticals, particularly radioligand therapies targeting oncology indications, pushes sponsors to rely on specialized contract partners for preclinical imaging, dosimetry, bioanalytical, and regulatory support work that requires radioisotope handling infrastructure few developers maintain internally. Rising sponsor interest in targeted alpha and beta emitter therapeutics is widening the addressable scope of outsourced radiopharmaceutical development work, as programs increasingly require specialized dosimetry modeling, radiochemistry, and short half-life logistics expertise concentrated within a limited pool of qualified contract partners. Growing isotope supply chain complexity, including constrained access to certain alpha-emitting precursor materials, is further reinforcing sponsor dependence on contract partners with established upstream isotope relationships and radiochemistry capability.

⮞RadioMedix expanded its thorium-228 supply network through a five-year frame agreement with Van Overeem Nuclear B.V. in December 2025, reinforcing the upstream isotope relationships increasingly required to support scaled targeted alpha therapy development.

U.S. Radiopharmaceutical CRO Market Outlook:

The U.S. Radiopharmaceutical CRO Market was valued at approximately USD 350 Million in 2025 and is projected to reach USD 820 Million by 2035, expanding at a CAGR of 8.75% over the forecast period.

Demand across the United States continued to be shaped by a dense concentration of clinical-stage radiopharmaceutical sponsors advancing targeted alpha and beta emitter oncology programs, sustained venture and public capital flow into radioligand therapy developers without internal manufacturing or dosimetry capability, and growing Department of Energy and commercial isotope supply agreements supporting domestic radiochemistry capacity. Sponsors across oncology and neurology programs continued favoring U.S.-based contract partners for proximity to clinical trial networks, established nuclear regulatory infrastructure, and the short half-life logistics that radiopharmaceutical development requires. Growing emphasis on regional drug-product finishing networks, positioned close to treatment sites to manage isotope decay during distribution, continued reinforcing capacity investment across the country, with specialized alpha-emitter handling capability emerging as a particular area of sponsor interest.

⮞Perspective Therapeutics continued expanding its U.S. drug-product finishing network in 2025, equipping newly acquired manufacturing buildings in Houston, Chicago, and Los Angeles alongside its Somerset, New Jersey site to support regional lead-212-labeled radiopharmaceutical distribution.

By Service Type: Preclinical Imaging and Biodistribution Studies Lead, Dosimetry Studies Grow Fastest

The Preclinical Imaging and Biodistribution Studies segment dominated the Radiopharmaceutical CRO Market, supported by the central role biodistribution data plays in every radiopharmaceutical program's early development package, regardless of whether the candidate is ultimately diagnostic or therapeutic in intent. Specialized imaging infrastructure, including small-animal PET and SPECT systems paired with radiochemistry support, keeps this work concentrated with a limited pool of contract partners that already hold the relevant radioactive materials licensing and facility approvals.

The Dosimetry Studies segment is growing fastest as regulatory expectations for therapeutic radiopharmaceutical programs increasingly require detailed organ- and tumor-level dose modeling to support both safety and efficacy claims. Rising adoption of patient-specific dosimetry software and modeling services is pulling investment toward specialized dosimetry capability, narrowing the gap with the imaging and biodistribution segment as more radioligand therapy programs advance into late-stage development.

By Radiopharmaceutical Type: Diagnostic Radiopharmaceuticals Dominate, Therapeutic/Radioligand Therapeutics Grow Fastest

The Diagnostic Radiopharmaceuticals segment dominated the Radiopharmaceutical CRO Market as PET and SPECT imaging agents remain the most mature and widely studied category of radiopharmaceutical candidates, with an established base of contract partners offering routine biodistribution and imaging support. The breadth of validated imaging protocols and reference data built around diagnostic agents continues to make this the default entry point for most sponsor programs.

The Therapeutic/Radioligand Therapeutics segment is the fastest growing as an expanding pipeline of targeted alpha and beta emitter therapies advances toward late-stage development and commercial launch. Rising sponsor investment in dedicated therapeutic radioisotope handling, dosimetry, and regulatory support capability is driving several contract partners to expand capacity specifically to capture this accelerating wave of therapeutic programs.

By Application: Oncology Leads, Neurology Grows Fastest

The Oncology segment dominated the Radiopharmaceutical CRO Market, reflecting the sustained volume of targeted alpha and beta emitter therapeutic programs and PET imaging agents developed for tumor detection and treatment response monitoring. Established preclinical oncology imaging infrastructure and radioligand dosimetry expertise have made specialized contract partners the default choice for sponsors advancing targeted cancer radiopharmaceuticals.

The Neurology segment is the fastest growing as an expanding pipeline of PET tracers and emerging therapeutic radiopharmaceuticals for neurodegenerative conditions increasingly requires specialized preclinical imaging and dosimetry support capable of tracking blood-brain barrier penetration and regional brain uptake, pushing sponsors toward contract partners with dedicated neuroimaging capability.

By End User: Pharmaceutical Companies Dominate, Biotechnology Companies Grow Fastest

The Pharmaceutical Companies segment dominated the Radiopharmaceutical CRO Market as large sponsors with established radiopharmaceutical portfolios continue to outsource specialized imaging, dosimetry, and regulatory support work that requires facility licensing and radioisotope handling infrastructure most efficiently accessed through specialized contract partners rather than built internally across every development site.

The Biotechnology Companies segment is the fastest growing as an expanding population of venture-backed radioligand therapy developers without internal manufacturing or dosimetry capability increasingly depends on contract partners for discovery-through-clinical support. Rising capital flow into targeted radiopharmaceutical startups is reinforcing this outsourcing preference across the sector.

Regional Analysis:

North America Radiopharmaceutical CRO Market Insights

North America dominated the Radiopharmaceutical CRO Market with the largest revenue share of approximately 38.90% in 2025, supported by the region's concentration of clinical-stage radiopharmaceutical sponsors, deep capital markets access for radioligand therapy developers, and an established base of contract partners offering integrated imaging, dosimetry, and regulatory support capability. The region's nuclear regulatory infrastructure and Department of Energy isotope supply relationships continue to make North American facilities a preferred first point of qualification for sponsors advancing novel radiopharmaceutical candidates. Ongoing consolidation among regional radiopharma CDMOs and CROs is further concentrating specialized isotope handling and dosimetry capability among a smaller number of well-resourced partners able to support programs from preclinical through commercial launch.

The United States accounted for the substantial majority of regional revenue, anchored by sustained radioligand therapy approval and pipeline volume, growing domestic isotope production investment, and a dense cluster of contract partners serving both coastal biotech hubs and specialized nuclear medicine research centers. Canada continued contributing a smaller but steady share of regional capacity, supported by established isotope production infrastructure and specialized imaging contract partners serving cross-border sponsor programs linked to the broader North American nuclear medicine supply chain.

Europe Radiopharmaceutical CRO Market Insights

Europe accounted for a significant share of global revenue, supported by a long-established base of nuclear medicine research expertise, strong national investment in radiopharmaceutical manufacturing infrastructure, and a regulatory environment that has historically supported specialized contract partners for complex isotope handling and dosimetry work. Decades of accumulated radiochemistry knowledge across the region's established nuclear medicine centers continue to attract sponsors seeking partners capable of handling demanding isotope logistics.

Germany continued to lead regional demand at roughly 22.80% of European revenue, supported by its established nuclear medicine research base and a concentration of contract partners offering imaging and dosimetry capability, while France and Belgium continued contributing significant isotope production and radiochemistry capacity to the regional market. The Netherlands also retained a specialized role in upstream isotope supply, anchored by established medical radionuclide producers serving contract partners across the region.

Asia Pacific Radiopharmaceutical CRO Market Insights

Asia Pacific is advancing at the fastest pace, growing at a CAGR of approximately 10.70% from 2026 to 2035, driven by sustained capacity investment from regional contract manufacturers and research organizations, expanding clinical trial volume for radiopharmaceutical candidates, and rising sponsor confidence in the region's nuclear medicine regulatory and quality infrastructure following years of facility modernization. Multinational sponsors are increasingly qualifying regional facilities as secondary manufacturing and testing sites, reflecting growing comfort with the region's quality systems.

China held a substantial share of regional revenue, supported by an expanding base of integrated contract partners offering imaging, dosimetry, and radiochemistry capability, while Japan and South Korea maintained specialized high-value nuclear medicine research niches and India continued strengthening its position in cost-competitive preclinical testing capacity. Australia also continued building out specialized cyclotron and isotope production infrastructure supporting regional sponsor demand.

MEA and Latin America Radiopharmaceutical CRO Market Insights

The Middle East and Africa and Latin America both showed steady growth, driven by expanding nuclear medicine infrastructure investment, rising local demand for diagnostic radiopharmaceutical imaging services, and gradually increasing interest from global sponsors in diversifying production and testing capacity outside traditional manufacturing hubs.

Saudi Arabia led Middle East and Africa demand, supported by the country's nuclear medicine infrastructure investment initiatives, while Brazil led Latin America, benefiting from an established nuclear medicine research base and growing government support for domestic radiopharmaceutical production and testing capability.

Market Dynamics:

Growth Drivers: Rising Radioligand Therapy Pipeline and Expanding Isotope Supply Investment

The industry is driven by an accelerating pipeline of targeted alpha and beta emitter radioligand therapies and the growing preference among both large pharmaceutical sponsors and emerging radiopharmaceutical developers to route preclinical imaging, dosimetry, and regulatory support work to specialized contract partners rather than building internal radioisotope handling infrastructure for programs with uncertain long-term volume requirements. Developers without internal manufacturing or dosimetry capability continue to view outsourced support as a way to preserve capital while accessing facility licensing and radiochemistry expertise that would otherwise take years to establish internally. Growing clinical validation of radioligand therapy as a distinct oncology treatment modality continues reinforcing sponsor willingness to invest in dedicated preclinical and dosimetry support programs well ahead of pivotal trial readouts.

Rising investment in upstream isotope supply, including expanded thorium-228, actinium-225, and lutetium-177 production agreements, continues supporting capacity investment, as oncology-focused sponsors increasingly require secured isotope access to advance targeted alpha and beta emitter programs. The expanding pipeline of theranostic imaging-therapy pairs continues to reinforce this dynamic, pushing leading contract partners to add dedicated radiochemistry and dosimetry capacity well ahead of confirmed long-term demand, with several providers also expanding regional finishing facilities to manage decay-related distribution constraints.

Restraints: Isotope Supply Constraints and Short Half-Life Logistics Complexity

Persistent constraints on the global supply of certain alpha- and beta-emitting isotopes, particularly actinium-225 and lutetium-177, continue posing a restraint, with sponsors often facing extended lead times for isotope access during periods of elevated demand concentrated among a limited pool of qualified producers. Smaller sponsors in particular can find themselves competing for the same constrained isotope supply as larger, better-resourced programs, which can delay study timelines and push sponsors toward securing their own long-term supply agreements earlier than planned.

Short half-life logistics complexity continues posing execution risk, particularly for therapeutic radiopharmaceutical programs where isotope decay during transport and distribution can compromise study or treatment timing. These challenges are often compounded when a program relies on contract partners located far from clinical trial sites, requiring additional regional drug-product finishing infrastructure to manage decay-related timing constraints and adding meaningful cost to programs that serve geographically dispersed trial networks.

Opportunities: Theranostic Expansion and Emerging Market Capacity Growth

Rising adoption of theranostic imaging-therapy pairing, where a diagnostic radiotracer identifies patients likely to respond to a matched therapeutic radioligand, represents a significant opportunity for contract partners able to combine imaging and therapeutic radiochemistry expertise within a single integrated service offering. Sponsors lacking this combined capability internally are increasingly turning to specialized radiopharmaceutical CROs to remain competitive in this fast-growing category, particularly as regulators increasingly expect theranostic development programs to demonstrate coordinated imaging and therapeutic data packages.

Expanding capacity investment across Asia Pacific and emerging nuclear medicine hubs offers a second substantial opportunity, as sponsors seeking to diversify isotope supply and testing capacity beyond traditional manufacturing regions increasingly qualify additional contract partners to reduce geographic concentration risk and secure more resilient upstream isotope relationships. This diversification trend is creating room for a broader set of regional contract partners to win qualification from multinational sponsors that previously concentrated supply in a single region.

Radiopharmaceutical CRO Market key players are:

• Charles River Laboratories International, Inc.

• Medpace Holdings, Inc.

• Pharmaron Beijing Co., Ltd.

• Labcorp Drug Development

• PAREXEL International Corporation

• IBA RadioPharma Solutions

• Eckert & Ziegler AG

• Curium Pharma

• Cardinal Health, Inc.

• NorthStar Medical Radioisotopes, LLC

• Jubilant Radiopharma

• ImaginAb, Inc.

• Invicro (Konica Minolta)

• PerkinElmer, Inc.

• Siemens Healthineers AG

• Bioscan, Inc.

• Novartis AG

• Lantheus Holdings, Inc.

• SOFIE Biosciences, Inc.

• Nucleus RadioPharma

Radiopharmaceutical CRO Market Report Scope: